Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009080637 - COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

Publication Number WO/2009/080637
Publication Date 02.07.2009
International Application No. PCT/EP2008/067681
International Filing Date 17.12.2008
IPC
C07C 311/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
02of an acyclic saturated carbon skeleton
08having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 213/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
24with substituted hydrocarbon radicals attached to ring carbon atoms
28Radicals substituted by singly-bound oxygen or sulfur atoms
30Oxygen atoms
C07D 213/65 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62Oxygen or sulfur atoms
63One oxygen atom
65attached in position 3 or 5
C07D 213/643 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62Oxygen or sulfur atoms
63One oxygen atom
64attached in position 2 or 6
6432-Phenoxypyridines; Derivatives thereof
A61K 31/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
18Sulfonamides
A61K 31/44 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
CPC
A61P 25/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07C 2602/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2602Systems containing two condensed rings
02the rings having only two atoms in common
04One of the condensed rings being a six-membered aromatic ring
08the other ring being five-membered, e.g. indane
C07C 311/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
02of an acyclic saturated carbon skeleton
08having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 213/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
24with substituted hydrocarbon radicals attached to ring carbon atoms
28Radicals substituted by singly-bound oxygen or sulfur atoms
30Oxygen atoms
C07D 213/643
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62Oxygen or sulfur atoms
63One oxygen atom
64attached in position 2 or 6
6432-Phenoxypyridines; Derivatives thereof
Applicants
  • GLAXO GROUP LIMITED [GB]/[GB] (AllExceptUS)
  • BERTHELEME, Nicolas [FR]/[GB] (UsOnly)
  • CHAN, Wai, Ngor [GB]/[GB] (UsOnly)
  • SCOTT, Jaqueline, Sandra [GB]/[GB] (UsOnly)
  • WARD, Simon, E. [GB]/[GB] (UsOnly)
Inventors
  • BERTHELEME, Nicolas
  • CHAN, Wai, Ngor
  • SCOTT, Jaqueline, Sandra
  • WARD, Simon, E.
Agents
  • KONDO, Rie
Priority Data
0724783.619.12.2007GB
0818068.902.10.2008GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
(FR) COMPOSÉS POTENTIATEURS DU RÉCEPTEUR AMPA ET LEURS UTILISATIONS DANS LE DOMAINE MÉDICAL
Abstract
(EN)
Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; and R2 is selected from H and CH3 when n is 1 and R2 is H when n is 2 or 3. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
(FR)
La présente invention concerne des composés de formule (I) et leurs sels, dans laquelle: n est 0, 1, 2 ou 3; R1 est choisi parmi phényle et pyridyle, l'un et l'autre étant éventuellement substitués par un ou deux groupes choisis indépendamment parmi alkyle C1-4 et halogène ; et R2 est choisi parmi H et CH3 lorsque n est 1 et R2 est H lorsque n est 2 ou 3. L'invention concerne également leurs procédés de préparation, des compositions pharmaceutiques, et leurs utilisations en tant que médicament, par exemple dans le traitement d'une maladie ou condition liée à une réduction ou un déséquilibre dans la fonction du récepteur de glutamate, telle que la schizophrénie ou la déficience cognitive.
Latest bibliographic data on file with the International Bureau